Evidence map›Paper›PMID 32096651›Full record

ArticleBioTechniques2020

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.

Liaqat Ali, Gauri Saxena, Meleri Jones, Georgia R Leisegang, Luke Gammon, Sharmilee Gnanapavan, Gavin Giovannoni, Klaus Schmierer, David Baker, Angray S Kang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioTechniques, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Detecting and predicting neutralization of alemtuzumab responses in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liaqat AliBarts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
Gauri SaxenaBarts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
Meleri JonesBarts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
Georgia R LeisegangCentre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
Luke GammonBarts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
Sharmilee GnanapavanBartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
Gavin GiovannoniBartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
Klaus SchmiererBartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
David BakerBartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
Angray S KangCentre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.ORCID 0000-0002-4672-4114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, NeutralizingAlemtuzumabAnimalsBinding, CompetitiveCD52 AntigenCHO CellsCricetulusCytological TechniquesFluoresceinsHumansImmunoassayLymphocyte DepletionMultiple SclerosisSulfonic AcidsAlemtuzumabalexa fluor 488Antibodies, NeutralizingCD52 AntigenFluoresceinsSulfonic Acidsalemtuzumabantidrug antibodiesmultiple sclerosisneutralizing antibodies

Identifiers

PMID32096651
PMCPMC7177201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.